Skip to content
Morepen Laboratories logo

Morepen Laboratories

MOREPENLAB NSE
₹101.33 −0.98 (−0.96%)
P/E
39.43
View as Markdown
MCP
Close 4 Nov 2026 ₹101.33 +53.86 +113% 1Y
Start ₹47.47

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
8.05%
Debt to Equity
0.17
EPS (TTM)
₹2.57
Book Value
₹25.21
Market Cap
—
P/E (TTM)
39.43
P/B
4.02
ROE
5.33%
Dividend Yield
0.20%
EBITDA
₹147 Cr
52W High
₹150.70
52W Low
₹33.05
Day Range
₹97.20 – ₹107.42
Volume
1,15,33,139

Peer Comparison

Healthcare › Pharmaceuticals

Morepen Laboratories peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Morepen Laboratories (this company)
₹101.3339.43₹5,326 Cr4.020.20%5.33%8.05%₹1,951 Cr₹141 Cr
Median 8 companies₹1,587.7039.12₹1,25,337 Cr4.570.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

40 Weak

Data confidence 100/100

surveillance:ASM4

Category scores

Quality
27
Poor
Returns, margins, earnings quality 22% weight
Valuation
49
Average
Cheap vs sector & own history 24% weight
Growth
32
Poor
Sales & profit trajectory 9% weight
Financial Health
53
Average
Solvency, leverage, coverage 9% weight
Momentum
96
Strong
Trend strength, vol-adjusted 12% weight
Ownership
75
Strong
FII/DII/promoter flows 24% weight
Capped: a governance trigger overrides the fundamentals here (surveillance:ASM4 ≤ 40).

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

3
  • Stock is trading at 5.95 times its book value
  • The company has delivered a poor sales growth of 8.73% over past five years.
  • Company has a low return on equity of 9.26% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallNeutral838
OscillatorsBullish234
Moving AveragesStrong Bearish604

Key readings

RSI (14)
35.62
Neutral
MACD (12,26,9)
−3.16
Bearish
SMA (50)
118.30
Bearish
SMA (200)
65.78
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+14.05%
5Y+8.74%
3Y+8.40%
1Y−0.33%
TTM+9.48%

Net profit

Net profit growth by window
10Y+22.13%
5Y−0.21%
3Y+35.02%
1Y−18.64%
TTM+51.61%

Operating cash flow

Operating cash flow growth by window
10Y−4.07%
5Y−8.34%
3YTurned positive
1Y+3.13%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−5.80 pp
5Y−3.04 pp
3Y+1.34 pp
1Y−2.62 pp
TTM+1.24 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹595 Cr
Mar 2018₹607 Cr
Mar 2019₹769 Cr
Mar 2020₹853 Cr
Mar 2021₹1,188 Cr
Mar 2022₹1,547 Cr
Mar 2023₹1,418 Cr
Mar 2024₹1,690 Cr
Mar 2025₹1,812 Cr
Mar 2026₹1,806 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹24.00 Cr
Mar 2018₹30.00 Cr
Mar 2019₹29.00 Cr
Mar 2020₹34.00 Cr
Mar 2021₹97.00 Cr
Mar 2022₹102 Cr
Mar 2023₹39.00 Cr
Mar 2024₹97.00 Cr
Mar 2025₹118 Cr
Mar 2026₹96.00 Cr

Quarterly Results

₹ Cr
MOREPENLAB quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
401
422
445
423
455
438
453
466
425
412
484
485
570
747
Expenses
375
388
394
375
404
394
417
424
401
381
438
460
488
623
Operating Profit
26
34
51
48
52
44
36
42
24
31
46
24
83
123
OPM %
7%
8%
11%
11%
11%
10%
8%
9%
6%
7%
10%
5%
14%
16%
Other Income
2
3
4
4
3
5
5
5
4
30
4
8
5
9
Interest
0
0
2
1
1
1
1
5
4
4
4
4
5
5
Depreciation
8
8
8
10
6
2
5
16
9
11
10
6
8
10
PBT
21
29
44
42
48
46
35
26
16
46
35
23
75
117
Tax %
29%
26%
27%
32%
25%
24%
24%
21%
26%
10%
22%
33%
24%
24%
Net Profit
15
21
32
28.28
36
35
27
20
11
41
28
16
56
89
EPS (₹)
0.29
0.42
0.63
0.55
0.71
0.64
0.49
0.37
0.2
0.75
0.5
0.29
1.03
—

Sep 2026: from the results filed on 27 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
MOREPENLAB profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
401
485
595
607
769
853
1,188
1,547
1,418
1,690
1,812
1,806
1,951
Expenses
352
424
534
542
701
785
1,070
1,410
1,338
1,532
1,638
1,680
1,767
Operating Profit
48
62
61
65
68
69
119
137
80
159
174
126
184
OPM %
12%
13%
10%
11%
9%
8%
10%
9%
6%
9%
10%
7%
9%
Other Income
1
−3
4
4
4
9
12
10
6
14
18
47
48
Interest
9
10
8
4
2
2
2
−7
2
4
8
16
17
Depreciation
39
35
34
34
40
37
30
28
28
33
29
36
36
PBT
2
13
24
30
29
39
99
127
56
135
155
120
179
Tax %
6%
−1%
0%
0%
1%
14%
1%
20%
31%
29%
24%
20%
—
Net Profit
2
13
24
30
29
34
97
102
39
97
118
96
141
EPS (₹)
0.05
0.28
0.53
0.66
0.64
0.75
2.16
2.13
0.76
1.88
2.15
1.73
2.57
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
9%
12%
—

Balance Sheet

₹ Cr
MOREPENLAB balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
90
90
90
90
90
90
90
96
102
102
110
110
Reserves
78
91
106
136
163
194
335
483
651
745
1,047
1,137
Borrowings
201
187
169
134
132
133
17
19
25
29
105
208
Other Liabilities
121
156
173
226
230
246
416
473
332
417
517
482
Total Liabilities
489
524
538
586
615
663
858
1,070
1,110
1,293
1,778
1,936
Fixed Assets
322
297
272
264
236
216
225
252
267
307
489
513
CWIP
0
0
0
0
0
0
2
14
17
24
28
22
Investments
0
0
0
0
0
1
1
0
0
1
85
124
Other Assets
167
227
266
321
379
446
631
804
827
960
1,176
1,277
Total Assets
489
524
538
586
615
663
858
1,070
1,110
1,293
1,778
1,936

Cash Flow

₹ Cr
MOREPENLAB cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
51
50
41
63
17
11
51
−60
−91
73
32
33
Investing
−32
−27
−14
−27
−13
−12
−70
−32
−47
−83
−322
−126
Financing
−19
−27
−24
−38
0
5
47
66
144
5
300
97
Net Cash Flow
0
−4
3
−1
4
4
28
−26
6
−5
10
4
Free Cash Flow
46
41
31
37
6
−6
10
−127
−137
−8
−182
−127
CFO/OP
105
81
66
98
26
25
44
−26
−94
70
40
46

Ratios

MOREPENLAB financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
51
66
57
73
64
59
56
59
68
70
65
67
Inventory Days
55
51
65
76
69
91
82
96
87
85
94
88
Days Payable
126
140
125
173
124
113
98
90
87
101
114
103
Cash Conversion Cycle
−20
−23
−3
−24
9
37
40
65
69
54
45
53
Working Capital Days
−20
−10
−86
−62
−34
−8
17
55
98
94
107
118
ROCE %
3%
8%
9%
9%
8%
10%
23%
23%
8%
17%
15%
8%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Morepen Laboratories insights

73 extracted metrics across FY06–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 46.71%
  • Promoters 35.65%
  • Others 12.48%
  • FIIs 3.43%
  • DIIs 1.71%
  • Government 0.01%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

  • Q1 FY27 concall · Aug 2026
    PPT
  • Concall · May 2026
    PPT
  • Q3 FY26 concall · Feb 2026
    PPT
  • Q2 FY26 concall · Nov 2025
    PPT
  • Q1 FY26 concall · Aug 2025
    PPT

Frequently Asked Questions about Morepen Laboratories

What does Morepen Laboratories Ltd do?
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.
Where is Morepen Laboratories Ltd (MOREPENLAB) listed?
Morepen Laboratories Ltd trades as MOREPENLAB on the NSE and under code 500288 on the BSE.
Which sector does Morepen Laboratories Ltd belong to?
Morepen Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Morepen Laboratories Ltd?
Morepen Laboratories Ltd trades at a PE ratio of 39.43 as of 4 Nov 2026, on earnings per share of ₹2.57, against a book value of ₹25.21 per share.
What is the 52-week high and low of Morepen Laboratories Ltd?
Over the last 52 weeks Morepen Laboratories Ltd has traded between ₹33.05 and ₹150.7 as of 4 Nov 2026.
Does Morepen Laboratories Ltd pay dividends?
Morepen Laboratories Ltd has a dividend yield of 0.20%.
What is the Return on Equity (ROE) of Morepen Laboratories Ltd?
Morepen Laboratories Ltd reported a return on equity of 5.33%. Its debt-to-equity ratio is 0.17.

Company Information

Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.

Website morepen.com
CEO Mr. Sushil Suri B.Sc., F.C.A.
Employees 1,814
Listed 24 Nov 1999
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MOREPENLAB.md for Morepen Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month